1523 related articles for article (PubMed ID: 11850229)
1. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
Howell A; Howell SJ; Clarke R; Anderson E
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
[TBL] [Abstract][Full Text] [Related]
2. Future use of selective estrogen receptor modulators and aromatase inhibitors.
Howell A
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4402s-4410s; discussion 4411s-4412s. PubMed ID: 11916232
[TBL] [Abstract][Full Text] [Related]
3. Are aromatase inhibitors superior to antiestrogens?
Howell A; Buzdar A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):237-47. PubMed ID: 15860266
[TBL] [Abstract][Full Text] [Related]
4. Selective oestrogen receptor modulators, aromatase inhibitors and the female breast.
Howell A
Curr Opin Obstet Gynecol; 2005 Aug; 17(4):429-34. PubMed ID: 15976552
[TBL] [Abstract][Full Text] [Related]
5. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
Johnston SR
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
[TBL] [Abstract][Full Text] [Related]
6. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
7. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
8. Emerging role of aromatase inhibitors in the adjuvant setting.
Goss PE
Am J Clin Oncol; 2003 Aug; 26(4):S27-33. PubMed ID: 12902874
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant trials of aromatase inhibitors: determining the future landscape of adjuvant endocrine therapy.
Ragaz J
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):133-41. PubMed ID: 11850217
[TBL] [Abstract][Full Text] [Related]
11. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
Jordan VC; Brodie AM
Steroids; 2007 Jan; 72(1):7-25. PubMed ID: 17169390
[TBL] [Abstract][Full Text] [Related]
12. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
Rugo HS
Ann Oncol; 2008 Jan; 19(1):16-27. PubMed ID: 17693420
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor effects of letrozole.
Miller WR; Anderson TJ; Dixon JM
Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
[TBL] [Abstract][Full Text] [Related]
14. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
15. Preliminary data from ongoing adjuvant aromatase inhibitor trials.
Goss PE
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4397s-4401s; discussion 4411s-4412s. PubMed ID: 11916231
[TBL] [Abstract][Full Text] [Related]
16. Challenges in the endocrine management of breast cancer.
Mouridsen HT; Rose C; Brodie AH; Smith IE
Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Rose C
Am J Clin Oncol; 2003 Aug; 26(4):S9-16. PubMed ID: 12902872
[TBL] [Abstract][Full Text] [Related]
18. The endocrine prevention of breast cancer.
Howell A
Best Pract Res Clin Endocrinol Metab; 2008 Aug; 22(4):615-23. PubMed ID: 18971122
[TBL] [Abstract][Full Text] [Related]
19. Use of aromatase inhibitors in breast carcinoma.
Santen RJ; Harvey HA
Endocr Relat Cancer; 1999 Mar; 6(1):75-92. PubMed ID: 10732791
[TBL] [Abstract][Full Text] [Related]
20. Local endocrine effects of aromatase inhibitors within the breast.
Miller WR; Dixon JM
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):93-102. PubMed ID: 11850212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]